News
-
-
PRESS RELEASE
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Dupixent achieves significant improvements in disease remission and symptoms in bullous pemphigoid study. Study met primary and key secondary endpoints with beneficial steroid-sparing effect -
-
-
-
PRESS RELEASE
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
New data shows Sarclisa induction therapy improves progression-free survival in transplant-eligible newly diagnosed multiple myeloma patients. GMMG-HD7 study results are promising for Sarclisa as part of frontline treatment -
-
-
-
PRESS RELEASE
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data showing high-sustained factor levels with once-weekly dosing in children with severe hemophilia A, effective bleed protection, and no inhibitor development to factor VIII
